Spatial Gene Expression Across Hepatic Lobule Zones: Mechanisms, Clinical Relevance, and Emerging Insights

Abstract

Spatial gene expression within hepatic lobule zones orchestrates the liver's extraordinary functional heterogeneity. Advances in spatial transcriptomics have illuminated how zonation patterns underpin metabolic compartmentalization and disease susceptibility. This review synthesizes current scientific knowledge on hepatic zonal gene expression, focusing on mechanistic underpinnings, clinical implications, and recent developments in diagnostic and therapeutic strategies. We highlight the translational significance of spatial transcriptomic profiling in understanding liver physiology, pathology, and the development of targeted interventions.

Introduction

The liver's architecture is defined by repeating hexagonal lobules, each comprising distinct metabolic zones periportal (zone 1), midzonal (zone 2), and pericentral (zone 3) regions. These zones are characterized by differential exposure to oxygen, nutrients, hormones, and xenobiotics, resulting in unique gene expression programs. The spatial distribution of gene expression within these zones not only underlies the organ's adaptive responses but also influences disease pathogenesis and therapeutic outcomes. Recent advances in spatial transcriptomic technologies have enabled high-resolution mapping of hepatic zonation, providing new avenues for research and clinical applications.

Epidemiology / Disease Burden

Liver disease remains a major global health concern, with nonalcoholic fatty liver disease (NAFLD), viral hepatitis, and cirrhosis contributing significantly to morbidity and mortality. The prevalence of NAFLD alone is estimated at 25% globally. Importantly, spatial heterogeneity in gene expression across lobular zones contributes to the selective vulnerability of hepatocytes to toxins, metabolic insults, and fibrogenic stimuli. Understanding zonal expression patterns is therefore crucial for elucidating the pathogenesis of common hepatic disorders and for stratifying disease risk.

Pathophysiology

Zonation in the hepatic lobule results from gradients in morphogens, oxygen tension, and metabolites. Wnt/β-catenin signaling predominates in pericentral hepatocytes, driving the expression of genes involved in xenobiotic metabolism (e.g., CYP450 enzymes) and glycolysis. Conversely, periportal zones exhibit higher expression of genes regulated by Hedgehog and Notch signaling, supporting gluconeogenesis, urea synthesis, and cholesterol metabolism. Disruption of these gradients via ischemia, fibrosis, or inflammation can perturb gene expression, leading to metabolic dysregulation, steatosis, or hepatocarcinogenesis. Spatial transcriptomics has revealed that disease progression often involves the expansion or contraction of specific zonal gene signatures, underscoring the dynamic nature of hepatic zonation.

Risk Factors

Risk factors influencing spatial gene expression and subsequent liver pathology include chronic alcohol intake, high-fat diets, viral infections (HBV, HCV), genetic mutations (e.g., in HFE or PNPLA3), and exposure to hepatotoxins. These factors may alter signaling gradients or directly modulate the epigenetic landscape of hepatocytes, leading to zone-specific vulnerability. For instance, pericentral hepatocytes are particularly susceptible to acetaminophen toxicity due to high CYP2E1 expression, while periportal regions are often affected in autoimmune hepatitis and primary biliary cholangitis.

Clinical Features

Clinical manifestations of liver disease often reflect the underlying spatial heterogeneity of gene expression. Steatosis and steatohepatitis typically begin in the pericentral region, progressing to panlobular involvement with advancing disease. Zonal necrosis, as seen in ischemic hepatitis, and zone-specific fibrosis, characteristic of chronic viral hepatitis, further illustrate the clinical relevance of hepatic zonation. Biomarkers reflecting spatial gene expression, such as glutamine synthetase (a pericentral marker), have emerged as tools for histopathological diagnosis and prognostication.

Diagnosis

Traditional liver histology remains the gold standard for assessing zonal pathology, but recent developments in spatial transcriptomics and single-cell RNA sequencing have revolutionized our diagnostic capabilities. These techniques enable the precise mapping of gene expression within individual lobule zones, facilitating early detection of dysregulated pathways and microenvironmental changes. Integration of spatial gene expression data with imaging modalities and serum biomarkers holds promise for noninvasive disease profiling, subtyping, and monitoring therapeutic response.

Treatment & Management

Understanding spatial gene expression patterns is increasingly informing therapeutic strategies. Targeted therapies that modulate zone-specific signaling pathways (e.g., Wnt inhibitors for hepatocellular carcinoma) are under investigation. Precision medicine approaches aim to tailor interventions based on individual zonal gene expression profiles, improving efficacy while minimizing off-target effects. Lifestyle modifications, pharmacological agents, and liver transplantation remain mainstays of management, but the incorporation of spatial transcriptomic insights is expected to enhance outcomes through more personalized interventions.

Recent Advances / Emerging Therapies

Recent years have witnessed rapid advances in spatial transcriptomics, single-molecule fluorescence in situ hybridization (smFISH), and multiplex imaging, allowing unprecedented resolution in mapping hepatic gene expression. Emerging therapies include gene editing (e.g., CRISPR-Cas9) targeting zonal pathways, RNA-based therapeutics, and small molecules modulating morphogen gradients. Notably, the use of patient-derived liver organoids and spatial omics platforms is facilitating the discovery of novel drug targets and biomarkers, accelerating the translation of basic research into clinical practice.

Guideline Recommendations

Current clinical guidelines emphasize the importance of integrating molecular and spatial data in liver disease assessment and management. The American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) recommend a multidisciplinary approach, incorporating histopathological, molecular, and imaging findings. As spatial transcriptomic techniques become more accessible, future guidelines are expected to adopt zone-specific biomarkers and risk stratification models in routine clinical workflows.

Conclusion

Spatial gene expression across hepatic lobule zones is fundamental to liver physiology and disease. Advances in spatial transcriptomics are transforming our understanding of hepatic zonation, revealing new opportunities for precision diagnostics and therapeutics. Continued integration of spatial omics into clinical practice promises to refine disease classification, risk assessment, and targeted treatment, ultimately improving outcomes for patients with liver disease.